Loading clinical trials...

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance | Clinical Trials | Clareo Health

TERMINATEDNA

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

NCT04150705•Washington University School of Medicine

Summary

The goal of pilot study is to assess the feasibility of FDG-PET/MRI for monitoring rectal cancer disease status in the setting of rectal cancer non-operative management (NOM). Data from this study will be used to guide the design of future clinical trials involving FDG-PET/MRI for rectal cancer NOM.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•At least 18 years of age
•Biopsy-proven rectal adenocarcinoma of the rectum with clinically suspected or previously known stage I-IIIB (cT1-4, N0-2, M0) disease
•Anticipated or prior chemoradiation as part of an NOM treatment strategy
•Ability to understand and willingness to sign an IRB-approved written informed consent document

Exclusion Criteria

•Prior surgical resection of rectal cancer (endoscopic or TME)
•Contraindication to MRI
•Comorbidities that would limit patient's ability to cooperate with a PET/MRI examination (e.g. dementia, inability to follow commands, claustrophobia, tremors, requirement for oxygen by nasal cannula, etc…).
•Implanted devices or materials that may interfere with MRI imaging or create significant artifact
•Pregnancy
•Contraindication to gadolinium contrast or FDG
•End-stage renal disease

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

June 1, 2020

Primary Completion Date

September 1, 2022

Completion Date

September 1, 2022

Last Updated

February 14, 2023

Enrollment

ACTUAL participants

Conditions

Rectal CancerCancer of the Rectum

Interventions

FDG PET/MRI

DEVICE

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors